Vantage Point: Qualitative Marketing Research

BJ Kirschner
BJ Kirschner

Entering, as of this writing, my second week of my new job, I saw this as the perfect time to opine on the future of qualitative marketing research. Or so I thought. In nearly 20 years of it, I am 100% sure of only one thing: qual research will not fundamentally change. For all the advances in technology and methodology, qualitative research cannot shed its history like its quant sibling.

Qual research is personal, tactile, emotional and fully present, based on visceral human responses. Changes in methodologies and technologies have merely made it easier for clients and respondents to interact; none have upended the purpose. Screeners have barely changed over time, especially the all-important amount of knowledge the clients want the respondents to have, or not have, about the research. Whether they want surprise or expertise, it's still a calculated decision to elicit reactions from ideal respondents.

So, wait—qual research, which now moves at the speed of light, is also coasting? How? The respondents. One of my mantras over the years has been, “That is not respondent #4. That is a living, breathing person sitting in a chair or on the phone, being asked to give opinions and feedback—who she is and what she has to say are more important than any number she represents.” Keep that in mind at every step of qual research, and you have the best possible attitude for success.

Thus, assuring that qual research has a future, no matter the form, is all about cultivating quality respondents who are eager to be a part of the process. The competition to get to them is intense, but it has to be: they make us shine, not the reverse.

BJ Kirschner is the newly appointed director, research operations, USA, at All Global.
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.